Literature DB >> 25317361

Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.

O Greg Deardorff, Ahsan Syed, Chelsea J Ames, Jaclyn S Yaeger1.   

Abstract

Entities:  

Year:  2014        PMID： 25317361      PMCID： PMC4195633          DOI： 10.4088/PCC.13l01598

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  17 in total

Review 1.  Weight considerations in psychotropic drug prescribing and switching.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  Postgrad Med       Date:  2013-09       Impact factor: 3.840

2.  Energy expenditure and physical activity in clozapine use: implications for weight management.

Authors:  Jenny-Kay Sharpe; Terry J Stedman; Nuala M Byrne; Connie Wishart; Andrew P Hills
Journal:  Aust N Z J Psychiatry       Date:  2006-09       Impact factor: 5.744

3.  Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects.

Authors:  Margaret K Hahn; Gary Remington; Daniel Bois; Tony Cohn
Journal:  J Clin Psychopharmacol       Date:  2010-12       Impact factor: 3.153

4.  Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.

Authors:  Istvan Bitter; Martin R K Dossenbach; Shlomo Brook; Peter D Feldman; Stephen Metcalfe; Carlo A Gagiano; János Füredi; György Bartko; Zoltan Janka; Csaba M Banki; Gabor Kovacs; Alan Breier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-01       Impact factor: 5.067

5.  Prevalence of childhood and adult obesity in the United States, 2011-2012.

Authors:  Cynthia L Ogden; Margaret D Carroll; Brian K Kit; Katherine M Flegal
Journal:  JAMA       Date:  2014-02-26       Impact factor: 56.272

6.  [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].

Authors:  Andrea López-Mato; Javier Rovner; Gonzalo Illa; Alejandra Vieitez; Oscar Boullosa
Journal:  Vertex       Date:  2003 Jun-Aug

7.  Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

Authors:  William T Regenold; Ramesh K Thapar; Christopher Marano; Sridevi Gavirneni; Prasad V Kondapavuluru
Journal:  J Affect Disord       Date:  2002-06       Impact factor: 4.839

8.  Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.

Authors:  Patrizia Cavazzoni; Yoko Tanaka; Suraja M Roychowdhury; Alan Breier; David B Allison
Journal:  Eur Neuropsychopharmacol       Date:  2003-03       Impact factor: 4.600

9.  The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

Authors:  Michael Poyurovsky; Vered Tal; Rachel Maayan; Irit Gil-Ad; Camil Fuchs; Abraham Weizman
Journal:  Eur Neuropsychopharmacol       Date:  2004-08       Impact factor: 4.600

Review 10.  The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.

Authors:  Daphne P Guh; Wei Zhang; Nick Bansback; Zubin Amarsi; C Laird Birmingham; Aslam H Anis
Journal:  BMC Public Health       Date:  2009-03-25       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.